Join to View Full Profile
55 Fruit St# MghBoston, MA 02114
Phone+1 617-724-4000
Fax+1 617-643-1915
Dr. Abramson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Icahn School of Medicine at Mount SinaiClass of 2000
Certifications & Licensure
MA State Medical License 2002 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014, 2017
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2017
Clinical Trials
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
- Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma Start of enrollment: 2008 Jun 01
- Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma Start of enrollment: 2008 Sep 01
Publications & Presentations
PubMed
- Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass
Blood Advances. 2026-05-12 - Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.Lara Stepan, Sahar Ansari, Jeremy S Abramson, Abood Okal, Justine Dell'Aringa
Journal of Clinical Oncology. 2026-04-27 - 1 citationsBrentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.Jeremy S Abramson, David J Straus, Nancy L Bartlett, John M Burke, Ryan C Lynch
Blood. 2026-04-09
Abstracts/Posters
- High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD EvaluationJeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial re...2019 ASCO Annual Meeting - 6/1/2019
- Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene mara...2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People with Relapsed or Refractory Diffuse Large B-cell LymphomaJuly 18th, 2025- Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCLDecember 6th, 2024
- Transplant vs. CAR T in DLBCL: Not Always an Either/Or QuestionOctober 21st, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
